Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE II: AART for Progressive Idiopathic Pulmonary Fibrosis
NCT07674745Phase 2Not yet recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Dec 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, intravenous immunoglobulin G in idiopathic pulmonary fibrosis (IPF), sponsored by University of Alabama at Birmingham. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
rituximabintravenous immunoglobulin G
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07674745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674745.